Endotoxin adsortion as adjuvant therapy in gramnegative severe sepsis;La depuracion de endotoxina como tratamiento coadyuvante en la sepsis grave por microorganismos gramnegativos

Revista Espanola de Quimioterapia

Volumn 23, Issue 3, 2010, Pages 115-121

  Candel, F J ^a   Martinez Sagasti F ^a   Borges, M M ^b   Maseda, E ^c   Herrera Gutierrez M ^d   Garnacho Montero, J ^e   Maynar, F J ^f   Zaragoza, R ^g   Mensa, J ^h   Azanza, J R ⁱ  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL SON LLÀTZER   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL TXAGORRITXU   (Spain)

^g HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Adsorption; Endotoxin; Polymyxin direct hemoperfusion.; Septic shock; Severe sepsis

Indexed keywords

BACTERIAL TOXIN; ENDOTOXIN; POLYMYXIN B; ANTIINFECTIVE AGENT; POLYMYXIN;

ADJUVANT THERAPY; ADSORPTION KINETICS; ARTICLE; DEVICE; DISEASE SEVERITY; EARLY INTERVENTION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; HEMOPERFUSION; HUMAN; MORTALITY; PATHOPHYSIOLOGY; SEPTIC SHOCK; ADSORPTION; CLINICAL TRIAL (TOPIC); GRAM NEGATIVE INFECTION; INTENSIVE CARE; ISOLATION AND PURIFICATION; MULTIMODALITY CANCER THERAPY; REVIEW; SEPSIS; SPAIN;

ADSORPTION; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CRITICAL CARE; ENDOTOXINS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMOPERFUSION; HUMANS; POLYMYXINS; SEPSIS; SPAIN;

EID: 78651359576     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36: 222-31.
2. Ferrer R, Artigas A, Levy MM, Blanco J, Gonzalez-Diaz G, Garnacho-Montero J, et al. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008; 299: 2294-303.
3. Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, et al. Design, conduct, analysis and reporting of a multinational placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008; 34: 1935-47.
4. Eisai Medical Research Inc. (Alec Wittek MD, Study Director). ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis. ClinicalTrialsgov Identifier: NCT00334828.
5. Data on file. Toray Medical Co, Ltd.
6. Sato T, Shoji H, Koga N. Endotoxin adsorption by polymyxin B immobilized fiber column in patients with systemic inflammatory response syndrome: the Japanese experience. Ther Apher Dial 2003 ; 7: 252-8.
7. Shimizu T, Endo Y, Tsuchihashi H, Akabori H, Yamamoto H, Tani T. Endotoxin apheresis for sepsis. Transfus Apher Sci 2006; 35: 271-82.
8. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420: 885-91.
9. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
10. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003 ; 31: 1250-6.
11. Antonelli M, Levy M, Andrews PJ, Chastre J, Hudson LD, Manthous C, et al. Hemodynamic monitoring in shock and implications for management. International Consensus Conference, Paris, France, 27-28 April 2006. Intensive Care Med 2007; 33: 575-90.
12. Palencia Herrejón E. La sepsis: definiciones y estadios. REMI http://remiuninetedu/2004/06/REMIC012004.
13. Candel FJ, Martinez-Sagasti F, Matesanz M, Gonzalez Del Castillo J, Ortuno F, Martin FJ, et al. Detection and initial management of the systemic inflammatory response syndrome in medicine emergency room: 24 hours follow-up in a general hospital. An Med Interna 2008; 25: 205-8.
14. Leon Gil C, Garcia-Castrillo Riesgo L, Moya Mir M, Artigas Raventos A, Borges Sa M, Candel Gonzalez FJ, et al. [Consensus document (SEMES-SEMICYUC). Recommendations for the initial and multidisciplinary diagnostic management of severe sepsis in the hospital Emergency Departments]. Med Intensiva 2007; 31: 375-87.
15. Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009 ; 37: 291-304.
16. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982 ; 307: 1225-30.
17. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gramnegative sepsis. The XOMA Sepsis Study Group. JAMA 1991; 266: 1097-102.
18. Ziegler EJ, Fisher CJ, Jr., Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991 ; 324: 429-36.
19. Martínez-Sagasti F. Ensayos clínicos en sepsis: un análisis crítico (primera parte). REMI 2009;9(10):A110. http://remiuninetedu/2009/10/REMIA110html
20. Martínez-Sagasti F. Ensayos clínicos en sepsis: un análisis crítico (segunda parte). REMI 2009;9(10):A111. http://remiuninetedu/2009/10/REMIA111html
21. Romaschin AD, Harris DM, Ribeiro MB, Paice J, Foster DM, Walker PM, et al. A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence. J Immunol Methods 1998; 212: 169-85.
22. Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004; 190: 527-34.
23. Bouman CS, Oudemans-van Straaten HM, Schultz MJ, Vroom MB. Hemofiltration in sepsis and systemic inflammatory response syndrome: the role of dosing and timing. J Crit Care 2007; 22: 1-12.
24. Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 2002; 28: 1434-9.
25. Rimmele T, Assadi A, Cattenoz M, Desebbe O, Lambert C, Boselli E, et al. High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant 2009; 24: 421-7.
26. Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 2003; 7: 108-14.
27. Aoki H, Kodama M, Tani T, Hanasawa K. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994; 167: 412-7.
28. Ruberto F, Pugliese F, D'Alio A, Martelli S, Bruno K, Marcellino V, et al. Clinical effects of use polymyxin B fixed on fibers in liver transplant patients with severe sepsis or septic shock. Transplant Proc 2007; 39: 1953-5.
29. Vincent JL, Laterre PF, Cohen J, Burchardi H, Bruining H, Lerma FA, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005; 23: 400-5.
30. Ronco C. The place of early haemoperfusion with polymyxin B fibre column in the treatment of sepsis. Crit Care 2005; 9: 631-633. (Pubitemid 43174476)
31. Tani T, Hanasawa K, Endo Y, Yoshioka T, Kodama M, Kaneko M, et al. Therapeutic apheresis for septic patients with organ dysfunction: hemoperfusion using a polymyxin B immobilized column. Artif Organs 1998; 22: 1038-44.
32. Nemoto H, Nakamoto H, Okada H, Sugahara S, Moriwaki K, Arai M, et al. Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 2001; 19: 361-8; discussion 8-9.
33. Nakamura T, Matsuda T, Suzuki Y, Shoji H, Koide H. Polymyxin B-immobilized fiber hemoperfusion in patients with sepsis. Dial Transplant 2003; 32: 602-7.
34. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007; 11: R47.
35. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301: 2445-52.
36. Vincent JL. Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA 2009; 302: 1968; author reply 9-70.
37. Amaral AC. Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA 2009 ; 302: 1968-1969; author reply 9-70.
38. Kida Y. Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA 2009; 302: 1969; author reply -70.
39. Maynar J, Herrera M, Martí F, Sánchez-Izquierdo JA, Martínez-Sagasti F, Fonseca F. Hemoperfusion with Toraymyxin in patients with severe sepsis due to intestinal perforation. Inflamm Res 2007; 56 (Supp):S238.
40. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 133-64.
41. Novelli G, Ferretti G, Poli L, Pretagostini R, Ruberto F, Perrella SM, et al. Clinical results of treatment of postsurgical endotoxin-mediated sepsis with polymyxin-B direct hemoperfusion. Transplant Proc 2010; 42: 1021-24.